🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

11,276 results for “Te” Clear

  1. MYCOPHENOLATE MOFETIL, IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Adult patients (age ≥18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), unresectable Stage IV, and who are chemotherapy-naïve.

    phase 3 small molecule active

    1 trial

  2. MYCOPHENOLATE MOFETIL, PREDNISOLONE , MYCOPHENOLATE MOFETIL, AZATHIOPRINE, Gazyvaro 1,000 mg concentrate for solution for infusion., AZATHIOPRINE

    Pari Pharma GmbH

    lupus nephritis

    phase 3 small molecule active

    1 trial

  3. MYCOPHENOLIC ACID, -, MYCOPHENOLATE MOFETIL, VAY736, TENOFOVIR ALAFENAMIDE , ENTECAVIR , TENOFOVIR DISOPROXIL

    Novartis Pharmaceuticals

    Lupus nephritis

    phase 3 small molecule active

    1 trial

  4. MYCOPHENOLIC ACID, TENOFOVIR ALAFENAMIDE , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe , Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, VAY736, ENTECAVIR , -, TENOFOVIR DISOPROXIL , VAY736, MYCOPHENOLATE MOFETIL

    Novartis Pharmaceuticals

    Lupus nephritis

    phase 3 small molecule active

    1 trial

  5. MaaT013

    Lacuna Pharma Pty Ltd

    Treatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.

    phase 3 small molecule active

    1 trial

  6. MabThera 500 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Glofitamab, RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsed or refractory diffuse large B-cell lymphoma

    phase 3 small molecule active

    1 trial

  7. MabThera 500 mg concentrate for solution for infusion, Polivy 140 mg powder for concentrate for solution for infusion., GEMCITABINE , OXALIPLATIN

    Hoffmann-La Roche

    Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  8. Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study

    The George Institute

    Maintenance treatment in metastatic non-squamous lung cancer

    phase 3 other active

    1 trial

  9. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

    phase 3 small molecule active

    1 trial

  10. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 3 small molecule completed

    3 trials

  11. Maridebart cafraglutide

    Amgen

    Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

    phase 3 small molecule active

    1 trial

  12. Matched placebo for test product, Duvakitug

    Sanofi-aventis Healthcare Pty Ltd

    Immune system disseases

    phase 3 small molecule active

    1 trial

  13. Matched placebo for test product, Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Chronic rhinosinusitis with nasal polyps

    phase 3 small molecule active

    1 trial

  14. Matched placebo for test product, Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Chronic rhinosinusitis with nasal polyps

    phase 3 small molecule active

    1 trial

  15. Matched placebo for test product, Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  16. Matches test film-coated tablets, Wakix 4.5 mg film-coated tablets, Wakix 18 mg film-coated tablets

    Bioprojet Pharma

    Narcolepsy

    phase 3 small molecule active

    1 trial

  17. Matching Placebo for Piclidenoson, Piclidenoson

    Can-Fite BioPharma

    Plaque psoriasis

    phase 3 small molecule active

    1 trial

  18. Matching placebo MGL-3196 60 mg film-coated tablet, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 100 mg film-coated tablet., MGL-3196 60 mg oral, MGL-3196 100 mg oral, MGL-3196 80 mg oral

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  19. Matching placebo for BAY 597939 2.5 mg filmcoated tablets, Rivaroxaban 2.5 mg

    The George Institute

    Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.

    phase 3 small molecule active

    1 trial

  20. Matching placebo for Tezepelumab solution for injection, TEZEPELUMAB

    AstraZeneca AB

    Severe Uncontrolled Asthma Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that asthma attacks are still occurring despite the use of other available treatments

    phase 3 small molecule active

    1 trial

  21. Matching placebo tablet, JNJ-67953964

    Janssen-Cilag International N.V.

    Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia

    phase 3 small molecule active

    1 trial

  22. Matching placebo tablet, JNJ-67953964

    Janssen-Cilag International N.V.

    Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia

    phase 3 small molecule active

    1 trial

  23. Mavorixafor, Placebo to Test IMP

    X4 Pharmaceuticals, Inc

    WHIM Syndrome

    phase 3 small molecule active

    1 trial

  24. Medi-546

    AstraZeneca

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources